ArticleEndocrinology, diabetes & metabolism case reports2025
Iatrogenic neonatal hyperphosphatemia due to phosphate-containing enema.
Article in Endocrinology, diabetes & metabolism case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Summary: Functional constipation is a common condition in infants. Phosphate-containing enemas (PCEs) are contraindicated in neonates due to the significant risk of severe electrolyte disturbances. We report a case of a 28-day-old neonate presenting with constipation and vomiting following the administration of PCEs. This resulted in hyperphosphatemia, hypocalcemia, and a prolonged QTc interval - critical conditions requiring urgent intervention. Management included hyperhydration, intravenous calcium gluconate, and oral alfacalcidol, which led to complete clinical recovery within 60 h. This case underscores the serious risks associated with inappropriate use of over-the-counter PCEs in neonates, even in the absence of underlying health conditions. It also highlights the importance of early recognition and effective supportive therapy to mitigate potential life-threatening complications. Learning points: Irritability and ECG anomalies can be the only signs and symptoms of severe acute hyperphosphatemia after administration of PCE. Clinicians should be aware of the risk of severe acute hyperphosphatemia after PCE administration in infants, even without comorbidities, due to a low PTH status. When symptomatic hypocalcemia occurs, intravenous calcium administration is warranted, as the risk of life-threatening consequences from hypocalcemia significantly outweighs the risk of developing metastatic calcifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.